Tag: bioconjugates
Preclinical Studies Show Significant Improved Therapeutic Index
Synaffix, a Netherlands-based biotechnology company exclusively focusing on the continued advancement of best-in-class and industry leading antibody-drug conjugate (ADC) technology platforms, has competed a new set...
A Chemistry Driven Approach to Uniform Antibody-drug Conjugates: New Data on...
Earlier today, during a plenary session of the 2015 World ADC Summit, being held October 26-29, 2014 in San Diego, California, Randall Halcomb, PhD, Vice President Chemistry at Igenica Biotherapeutics,
presented new data utilizing the company's SNAP site-specific ADC linker technology.
